30286-75-0

30286-75-0 structure
30286-75-0 structure

Name Tersigat
Synonyms oxytropiumbromide
Scopolamine ethobromide
oxytropium bromide
ba253br
(-)-n-ethyl-norhyoscine-methobromide
OXITROPIUM BROMIDE
Oxitropium
bromurodeoxitropio
(1R,2R,4S,5S,7s,9R)-9-ethyl-7-(((S)-3-hydroxy-2-phenylpropanoyl)oxy)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide
Oxitropium bromide
Ba-253-BR-L
oxitropium
N-Ethylnorscopolamine-methyl bromide
enylpropoxy)-9-methyl-,bromide,(7(s)-(1-alpha,2-beta,4-beta,5-alpha,7-beta))
Oxitropium bromide CRS
Oxitropiumbromid
Tersigan
N-Ethylnorscopolammonium bromide
Oxivent
ba-253-br-l
Ventilat
n-ethyl-norscopolaminemethobromide
N-Ethylscopolammonium bromide (6CI, 7CI)
tersigat
3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 9-ethyl-7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9-methyl-, bromide, (1a,2b,4b,5a,7b)- (9CI)
3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, [7(S)-(1a,2b,4b,5a,7b)]
Bromure d'oxitropium
Hyoscine ethobromide
N-Ethylnorscopolamine methylbromide
oxitropiobromuro
3-oxa-9-azoniatricyclo(3.3.1.0(sup2,4))nonane,9-ethyl-7-(3-hydroxy-1-oxo-2-ph
Description Oxitropium bromide is an mAChR antagonist used as an anticholinergic bronchodilator drug for the treatment of asthma and chronic obstructive pulmonary disease.
Related Catalog
Target

mAChR[1]

In Vitro Oxitropium bromide is a muscarinic antagonist which blocks musucarinic acetylcholine receptors (mAChR). Incubation with oxitropium bromide of untreated diaphragm muscle and diaphragm muscle injected with endotoxin does not increase the force-frequency curves dose-dependently in vitro; however, it causes both types of muscle to be fatigue resistant[1].
In Vivo Oxitropium bromide inhalation shifts force-frequency curves upward at 2 h after inhalation and inhibits the decrease of force-frequency curves due to endotoxin injection in vivo[1]. Oxitropium bromide strongly and persistently inhibits the acetylcholine (ACh)-induced resistance. The increase in resistance induced by histamine, serotonin, leukotriene D4 or antigen is prevented by oxitropium bromide oxitropium bromide[2]. Inhalation of the anticholinergic agent oxitropium bromide at doses of 1.5 μg and higher greatly attenuates the decrease in mucus score produced by intravenous histamine but not by inhaled histamine[3].
Animal Admin Mice: In the oxitropium bromide inhalation group, animals are given 2 puffs of inhalation from a oxitropium bromide MDI (metered dose inhaler) via a 75-mL spacer, and then diaphragm muscles are dissected and measured as to contractility immediately, 1 hour, 2 hours and 4 hours later (n=5 animals each). An animal is placed in a centrifugal tube (inner diameter=30 mm) with a round hole (diameter=10 mm) in the bottom, its nose and mouth being exposed through the hole to breath. An oxitropium bromide MDI (metered dose inhaler) releases 2 puffs into a spacer attached to the tube. Aerosols of oxitropium bromide are inhaled for about 10 seconds, while the animal is breathing spontaneously through the hole of the tube[1].
References

[1]. Shindoh C, et al. Effects of inhalation or incubation of oxitropium bromide on diaphragm muscle contractility in mice. Allergol Int. 2011 Sep;60(3):365-72.

[2]. Kohno SW, et al. Effect of oxitropium bromide (Ba253) on increased airway resistance induced by various agonists and antigen in the guinea pig. Jpn J Pharmacol. 1989 Aug;50(4):455-66.

[3]. Takeyama K, et al. Effect of oxitropium bromide on histamine-induced airway goblet cell secretion. Am J Respir Crit Care Med. 1996 Jul;154(1):231-6.

Melting Point 203-204° (dec)
Molecular Formula C19H26BrNO4
Molecular Weight 412.31800
Exact Mass 411.10500
PSA 59.06000

CHEMICAL IDENTIFICATION

RTECS NUMBER :
RN7090000
CHEMICAL NAME :
3-Oxa-9-azoniatricyclo(3.3.1.0(sup 2,4))nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)- 9-methyl-, bromide, (7(S)-(1-alpha,2-beta,4-beta,5-alpha,7-beta))-
CAS REGISTRY NUMBER :
30286-75-0
LAST UPDATED :
199512
DATA ITEMS CITED :
16
MOLECULAR FORMULA :
C19-H26-N-O4.Br
MOLECULAR WEIGHT :
412.37
WISWESSER LINE NOTATION :
T C356 A AK DOTJ A2 A1 HOVYR&1Q &E

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2250 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
19 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - changes in motor activity (specific assay) Lungs, Thorax, or Respiration - other changes
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 36,353,1988
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1600 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1150 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
25700 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
3 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
40 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - changes in motor activity (specific assay) Lungs, Thorax, or Respiration - other changes
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 36,353,1988
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
>8 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 35,435,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
34 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
55 gm/kg/13W-C
TOXIC EFFECTS :
Nutritional and Gross Metabolic - weight loss or decreased weight gain
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 36,353,1988
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
17 gm/kg/78W-C
TOXIC EFFECTS :
Gastrointestinal - decreased motility or constipation Related to Chronic Data - death
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 36,353,1988
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
2730 mg/kg/13W-C
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - conjunctive irritation Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 36,353,1988 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
55 gm/kg
SEX/DURATION :
male 10 week(s) pre-mating female 2 week(s) pre-mating female 1-7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 37,413,1989
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
6600 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 37,413,1989
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
7800 mg/kg
SEX/DURATION :
female 17-21 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - behavioral
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 37,413,1989
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2600 mg/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 37,413,1989

~%

30286-75-0 structure

30286-75-0

Literature: Journal of the American Chemical Society, , vol. 78, p. 3448,3452

~84%

30286-75-0 structure

30286-75-0

Literature: Banholzer; Pook Arzneimittel-Forschung/Drug Research, 1985 , vol. 35, # 1 A p. 217 - 228

~%

30286-75-0 structure

30286-75-0

Literature: Arzneimittel-Forschung/Drug Research, , vol. 35, # 1 A p. 217 - 228

~%

30286-75-0 structure

30286-75-0

Literature: Arzneimittel-Forschung/Drug Research, , vol. 35, # 1 A p. 217 - 228
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.